Avalo Therapeutics (NASDAQ:AVTX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Avalo Therapeutics (NASDAQ:AVTX) had its target price upped by equities researchers at HC Wainwright from $15.00 to $25.00 in a note issued to investors on Wednesday, Marketbeat.com reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 110.44% from the company’s current price.

Other research analysts also recently issued reports about the company. TD Cowen started coverage on Avalo Therapeutics in a research report on Friday, September 5th. They set a “buy” rating for the company. Cowen started coverage on Avalo Therapeutics in a research report on Friday, September 5th. They set a “buy” rating for the company. Finally, Cantor Fitzgerald assumed coverage on Avalo Therapeutics in a research report on Friday, August 15th. They set an “overweight” rating for the company. Nine equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $31.67.

Avalo Therapeutics Trading Up 4.9%

NASDAQ AVTX opened at $11.88 on Wednesday. Avalo Therapeutics has a one year low of $3.39 and a one year high of $16.00. The stock has a 50 day moving average price of $8.62 and a 200-day moving average price of $6.48.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Thursday, August 7th. The company reported ($1.92) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.49). On average, sell-side analysts predict that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

Institutional Trading of Avalo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock valued at $552,000 after buying an additional 2,648 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Avalo Therapeutics in the first quarter worth $80,000. Quadrature Capital Ltd purchased a new stake in Avalo Therapeutics in the second quarter worth $55,000. Boothbay Fund Management LLC purchased a new stake in Avalo Therapeutics in the second quarter worth $56,000. Finally, Northern Trust Corp purchased a new stake in Avalo Therapeutics in the fourth quarter worth $168,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.